Pacira | PCRX - Operating Profit


Pacira reported $13.15M in Operating Profit for its fiscal quarter ending in September of 2025.





Operating Profit Change Date
Assertio Holdings USD -3.05M 569K Sep/2024
Astellas Pharma JPY 134.54B 30.13B Dec/2025
Bristol-Myers Squibb USD 4.2B 562M Dec/2025
Cara Therapeutics USD -2.39M 3.49M Mar/2025
Coherus Biosciences USD -45.43M 3.13M Mar/2025
Heron Therapeutics USD -5.66M 782K Sep/2024
Ironwood Pharmaceuticals USD 33.22M 7.58M Dec/2024
J&J USD 5.59B 1.81B Dec/2025
Ligand Pharmaceuticals USD 158.89M 149.17M Sep/2025
Nektar Therapeutics USD -34.34M 15.43M Sep/2024
Novo Nordisk DKK 32.38B 1.7B Dec/2025
Omeros USD -35.41M 23.75M Sep/2024
Pacira USD 13.15M 2.92M Sep/2025
Perrigo USD 93.4M 37.8M Sep/2025
Pfizer USD 4.65B 3.99B Dec/2025
Supernus Pharmaceuticals USD 13.82M 74.01M Dec/2025
Teva Pharmaceutical Industries USD 487M 581M Dec/2025
Xeris Pharmaceuticals USD 6.73M 2.25M Sep/2025
Xoma USD -15.64M 5.56M Sep/2024
Zoetis USD 835M 101M Dec/2025